This ASX medical device company has a Trump tariff exemption

Did this ASX stock just receive a golden ticket?

| More on:
Ecstatic woman on her phone giving a fist pump after reading some good news.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

sdf

ResMed Inc (ASX: RMD) could be counting its lucky stars this week as it might be one of the few companies handed a tariff exemption from the Trump administration. 

The company develops, manufactures, distributes, and markets medical devices and cloud-based software solutions.

It operates through two segments, Sleep and Respiratory Care, and Software as a Service (SaaS).

According to Australian Financial Review, it has received an exemption from Donald Trump's trade tariffs. 

This means exports from its manufacturing hubs in Australia and Singapore can likely avoid the US president's global trade war.

Chief executive Mick Farrell told AFR the company manufactures sleep devices and masks in Australia and Singapore, which are protected under the Nairobi Protocol. This international agreement guarantees duty-free treatment for products that help people with disabilities.

We have a tariff exemption under this decades-old protection. The tax revenue wouldn't be material to the US government and there's no reason for them to want to turn over something and get constituents or citizens upset about not caring about people with disabilities.

ResMed rising

ResMed shares are up more than 5% over the last month. 

Created with Highcharts 11.4.3ResMed PriceZoom1M3M6MYTD1Y5Y10YALLwww.fool.com.au

This was possibly due to a strong Q3 update.

For the three months ended 31 March, ResMed reported an 8% increase in revenue to US$1.3 billion.

This was driven by increased demand for its sleep devices and masks portfolio, as well as solid growth across its Residential Care Software business.

Despite the positive tariff exemption news, Farrell reinforced there is still some uncertainty. Referring to the White House's control over government agencies that make decisions on tariffs, he said that "nothing is rock-solid when an administration, particularly this one, can make changes very quickly".

According to the AFR, ResMed is doubling its manufacturing capacity in the United States with a new plant in Calabasas, California, a move Farrell said was not a reaction to Trump administration policies.

What are brokers saying?

It seems brokers are bullish on this blue-chip stock, with multiple brokers placing attractive price targets on the stock thanks to the tariff exemption and strong financials. 

At the time of writing, shares are trading at $36.75 each. 

Macquarie has a price target $48.00, indicating a 30% upside. 

Analysts at Goldman Sachs have retained their conviction buy rating on ResMed shares with an improved price target of $49.30. This was also influenced by the tariff exemption.

Jed Richards from Shaw and Partners says Resmed is a buy

Richards said:

On April 24, ResMed posted an 8 per cent increase in revenue in the third quarter of fiscal year 2025. The gross margin improved 140 basis points to 59.3 per cent. Income from operations increased 14 per cent.

ResMed's innovative products and steady revenue growth make it a solid investment. 

Bell Potter has a $43.31 price target.

Motley Fool contributor Aaron Bell has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

A young man wearing a black and white striped t-shirt looks surprised.
Broker Notes

These ASX 200 shares could rise 25% to 80%

Analysts think big returns could be on offer from these shares.

Read more »

The silhouettes of ten people holding hands with their arms raised against the sky, as the sun rises or sets in the background.
Share Gainers

Here are the top 10 ASX 200 shares today

Investors were nervous this Friday, ending the week on a sour note.

Read more »

A businessman looking at his digital tablet or strategy planning in hotel conference lobby. He is happy at achieving financial goals.
Share Market News

Where to invest $5,000 into ASX 200 shares this month

The team at Bell Potter is bullish on these names. But why?

Read more »

Man pointing an upward line on a bar graph symbolising a rising share price.
52-Week Highs

8 ASX 200 shares hitting multi-year highs today

These shares have defied the trend, hitting new price milestones amid a day in the red for the ASX 200.

Read more »

Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A young man punches the air in delight as he reacts to great news on his mobile phone.
Share Gainers

Why EOS, Evolution Mining, Renascor, and Woodside shares are jumping today

These shares are ending the week on a high. But why?

Read more »

Person with thumbs down and a red sad face poster covering the face.
Share Fallers

Why Accent, Cettire, Ioneer, and Pro Medicus shares are dropping today

These shares are ending the week in the red. What's going on?

Read more »

A group of three miners in hard hats and high visibility vests confer at a rocky mining site.
Broker Notes

Up 66% in a year, just how much more upside does Macquarie tip for Perseus Mining shares?

Just how much higher might Perseus Mining shares soar? Here’s what Macquarie had to say about the ASX 200 gold…

Read more »